Skip to main content

Table 3 Comparison of clinical, laboratory and radiological data of studied cases with and without GHD

From: Effect of zinc supplementation on growth Hormone Insulin growth factor axis in short Egyptian children with zinc deficiency

  With GHD Without GHD t p
  (N = 25) (N = 25)   
Height SDS −3.52 ± 0.3 −2.56 ± 0.1 6.11 0.043*
(−2.85- -4.21) (−2.15- -2.91)   
GV (cm/3 months) 1.21 ± 0.2 0.85 ± 0.1 5.99 0.041*
(0.7-2.23) (0.1-1.83)   
GV SDS +1.56 ± 0.5 +0.91 ± 0.2 7.12 0.030*
(+0.72 - +2.11) (-0.5 - +1.86)   
Weight SDS -1.68 ± 0.12 -1.58 ± 0.52 1.9 0.5
(-1.99 - +0.55) (-2.01- +0.25)   
BMI (kg/m2) 16.91 ± 0.25 17.31 ± 0.46 1.8 0.3
(15.56-18.12) (14.53-17.92)   
BMI SDS -1.81 ± 0.10 -1.72 ± 0.32 2.1 0.5
(-1.9- -0.78) (-2.10- -0.82)   
Serum Zn (μg/dl) 45.71 ± 2.9 76.16 ± 5.9 18.12 <0.001***
(37.52-61.55) (39.12 - 93.11)   
Peak GH after insulin stimulation(ng/ml) 7.81 ± 0.1 11.61 ± 1.01 9.11 0.021*
(7.61-8.91) (10.55-13.20)   
Peak GH after clonidine stimulation (ng/ml) 7.14 ± 0.12 12.54 ± 1.21 10.16 0.01*
(6.92-8.53) (10.88-14.11)   
IGF-1 (ng/ml) 46.78 ± 6.5 100.12 ± 12.5 16.22 <0.001***
(36.52-59.11) (72.55-115.69)   
IGF-1 SDS -2.72 ± 0.10 +0.38 ± 0.21 19.01 <0.001***
(-3.22- -2.11) (-1.20- +0.55)   
IGFBP-3 (ng/ml) 2006.22 ± 92 3445.11 ± 292 9.88 0.01*
(1195.45 - 2111.26) (3124.45 - 3898.15)   
-BA (years) 2.8 ± 1.0 5.7 ± 1.26 8.15 0.03*
(1.81-5.9) (4.-9.25)   
-BA SDS -1.7 ± 0.12 -0.7 ± 0.14 11.22 0.01*
(-2.44 - +0.01) (-1.14 - +0.22)   
  1. Results are expressed as mean ± SD and range, *p < 0.05, **p < 0.01, ***p < 0.001, GHD: growth hormone deficiency, SDS: Standard deviation score, GV: growth velocity, BMI: Body mass index, Zn: zinc, GH: Growth hormone, IGF-1: Insulin like growth factor-1, IGFBP-3: Insulin like growth factor binding protein-3, BA: bone age.